Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Colorcon
Medtronic
Express Scripts
Boehringer Ingelheim

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,173,158


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,173,158 protect, and when does it expire?

Patent 8,173,158 protects DEXILANT and is included in one NDA.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-two patent family members in fifteen countries.

Summary for Patent: 8,173,158
Title:Methods of treating gastrointestinal disorders independent of the intake of food
Abstract: The present invention relates to a method of treating a gastrointestinal disorder by administering to a patient in need of treatment thereof a pharmaceutical composition, wherein said pharmaceutical composition can be administered to the patient independent of the intake of food.
Inventor(s): Lee; Ronald D. (Round Lake Beach, IL), Vakily; Majid (Gurnee, IL), Mulford; Darcy (Grayslake, IL), Wu; Jing-Tao (Mundelein, IL), Atkinson; Stuart (Lake Forest, IL)
Assignee: Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:12/249,258
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,173,158
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,173,158

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-001 Jan 30, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,173,158

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008310735 ⤷  Try it Free
Brazil PI0818286 ⤷  Try it Free
Canada 2702356 ⤷  Try it Free
China 102014638 ⤷  Try it Free
China 104069088 ⤷  Try it Free
Colombia 6260019 ⤷  Try it Free
European Patent Office 2203068 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Moodys
Mallinckrodt
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.